Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (12): 1157-1163.DOI: 10.3969/j.issn.1673-8640.2022.12.011
Previous Articles Next Articles
XU Runhao1, ZOU Chen2, CAO Yun1, CHEN Feng1, LIU Yijing1, ZHANG Shulin3, ZHANG Jie1()
Received:
2021-10-11
Revised:
2022-07-15
Online:
2022-12-30
Published:
2023-02-02
Contact:
ZHANG Jie,E-mail:Jane_zhanlin@sina.com。
CLC Number:
XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer[J]. Laboratory Medicine, 2022, 37(12): 1157-1163.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.12.011
组别 | 例数 | Ala/ (μmol/L) | Gly/ (μmol/L) | Leu/ (μmol/L) | Pro/ (μmol/L) | |
---|---|---|---|---|---|---|
正常对照组 | 80 | 481.02±103.69 | 327.35(286.29~357.34) | 175.81±39.90 | 190.55(159.60~217.98) | |
肺良性疾病组 | 65 | 454.02±116.35 | 322.41(282.71~367.71) | 165.56±33.01 | 178.87(146.18~219.41) | |
早期NSCLC组 | 64 | 534.02±116.33**## | 334.17(288.36~426.44) | 180.69±40.42# | 198.85(172.33~255.82)*## | |
中晚期NSCLC组 | 55 | 469.59±111.74△△ | 320.77(268.82~409.97) | 164.85±36.33△ | 185.61(158.39~214.44) | |
组别 | Phe/ (μmol/L) | Val/ (μmol/L) | Met/ (μmol/L) | Tyr/ (μmol/L) | Glu/ (μmol/L) | |
正常对照组 | 103.00(88.10~111.44) | 288.66±59.62 | 29.03±4.79 | 80.89±13.52 | 226.11(180.67~256.29) | |
肺良性疾病组 | 101.28(85.27~118.71) | 277.93±53.86 | 29.81±5.83 | 73.18±15.35 | 186.78(64.49~258.84) | |
早期NSCLC组 | 107.79(95.05~122.21) | 320.76±63.01**## | 30.18±7.62 | 78.44±17.64 | 248.27(212.99~302.44)**## | |
中晚期NSCLC组 | 100.15(88.02~111.11) | 281.36±57.58△△ | 29.85±6.13 | 78.46±19.01 | 198.48(182.78~238.07)△△ | |
组别 | Arg/ (μmol/L) | His/ (μmol/L) | Lys/ (μmol/L) | Cit/ (μmol/L) | Orn/ (μmol/L) | |
正常对照组 | 121.22±26.23 | 102.22±16.35 | 284.49±61.26 | 30.92(24.1~37.24) | 118.07(101.28~140.40) | |
肺良性疾病组 | 120.98±35.51 | 81.72±17.34 | 237.49±55.65 | 28.02(23.44~33.97) | 126.95(97.12~151.19) | |
早期NSCLC组 | 118.63±40.68 | 91.04±17.55**## | 262.60±60.81*# | 36.50(29.74~47.39)**## | 143.50(125.59~170.89)**## | |
中晚期NSCLC组 | 117.68±41.03 | 86.54±19.05 | 242.14±46.13△ | 32.88(30.38~38.71) | 134.80(116.18~164.58) |
组别 | 例数 | Ala/ (μmol/L) | Gly/ (μmol/L) | Leu/ (μmol/L) | Pro/ (μmol/L) | |
---|---|---|---|---|---|---|
正常对照组 | 80 | 481.02±103.69 | 327.35(286.29~357.34) | 175.81±39.90 | 190.55(159.60~217.98) | |
肺良性疾病组 | 65 | 454.02±116.35 | 322.41(282.71~367.71) | 165.56±33.01 | 178.87(146.18~219.41) | |
早期NSCLC组 | 64 | 534.02±116.33**## | 334.17(288.36~426.44) | 180.69±40.42# | 198.85(172.33~255.82)*## | |
中晚期NSCLC组 | 55 | 469.59±111.74△△ | 320.77(268.82~409.97) | 164.85±36.33△ | 185.61(158.39~214.44) | |
组别 | Phe/ (μmol/L) | Val/ (μmol/L) | Met/ (μmol/L) | Tyr/ (μmol/L) | Glu/ (μmol/L) | |
正常对照组 | 103.00(88.10~111.44) | 288.66±59.62 | 29.03±4.79 | 80.89±13.52 | 226.11(180.67~256.29) | |
肺良性疾病组 | 101.28(85.27~118.71) | 277.93±53.86 | 29.81±5.83 | 73.18±15.35 | 186.78(64.49~258.84) | |
早期NSCLC组 | 107.79(95.05~122.21) | 320.76±63.01**## | 30.18±7.62 | 78.44±17.64 | 248.27(212.99~302.44)**## | |
中晚期NSCLC组 | 100.15(88.02~111.11) | 281.36±57.58△△ | 29.85±6.13 | 78.46±19.01 | 198.48(182.78~238.07)△△ | |
组别 | Arg/ (μmol/L) | His/ (μmol/L) | Lys/ (μmol/L) | Cit/ (μmol/L) | Orn/ (μmol/L) | |
正常对照组 | 121.22±26.23 | 102.22±16.35 | 284.49±61.26 | 30.92(24.1~37.24) | 118.07(101.28~140.40) | |
肺良性疾病组 | 120.98±35.51 | 81.72±17.34 | 237.49±55.65 | 28.02(23.44~33.97) | 126.95(97.12~151.19) | |
早期NSCLC组 | 118.63±40.68 | 91.04±17.55**## | 262.60±60.81*# | 36.50(29.74~47.39)**## | 143.50(125.59~170.89)**## | |
中晚期NSCLC组 | 117.68±41.03 | 86.54±19.05 | 242.14±46.13△ | 32.88(30.38~38.71) | 134.80(116.18~164.58) |
来源 | NSCLC组/例 | 正常对照组/例 | 样本 类型 | Ala | Gly | Leu | Pro | Phe | ||
---|---|---|---|---|---|---|---|---|---|---|
总例数 | Ⅰ期 | Ⅱ期 | ||||||||
本研究 | 64 | 55 | 9 | 80 | 血清 | ↑↑ | — | — | ↑ | — |
MAEDA等[ | 136 | 69 | 8 | 423 | 血浆 | ↑↑ | ↑↑ | ↑↑ | ↑↑ | ↑↑ |
KLUPCZYNSKA等[ | 90 | 42 | 29 | 63 | 血清 | ↓ | — | — | ↓ | ↑↑ |
SHINGYOJI等[ | 75 | 33 | 5 | 323 | 血浆 | — | — | ↑↑ | ↑↑ | ↑↑ |
KIM等[ | 71 | 14 | 5 | 70 | 血浆 | ↓ | ↓ | ↓ | ↓ | — |
邹琛等[ | 95 | 14 | 12 | 90 | 血清 | ↓↓ | — | ↓↓ | — | — |
来源 | NSCLC组/例 | 正常对照组/例 | 样本 类型 | Ala | Gly | Leu | Pro | Phe | ||
---|---|---|---|---|---|---|---|---|---|---|
总例数 | Ⅰ期 | Ⅱ期 | ||||||||
本研究 | 64 | 55 | 9 | 80 | 血清 | ↑↑ | — | — | ↑ | — |
MAEDA等[ | 136 | 69 | 8 | 423 | 血浆 | ↑↑ | ↑↑ | ↑↑ | ↑↑ | ↑↑ |
KLUPCZYNSKA等[ | 90 | 42 | 29 | 63 | 血清 | ↓ | — | — | ↓ | ↑↑ |
SHINGYOJI等[ | 75 | 33 | 5 | 323 | 血浆 | — | — | ↑↑ | ↑↑ | ↑↑ |
KIM等[ | 71 | 14 | 5 | 70 | 血浆 | ↓ | ↓ | ↓ | ↓ | — |
邹琛等[ | 95 | 14 | 12 | 90 | 血清 | ↓↓ | — | ↓↓ | — | — |
组别 | 例数 | CA 19-9/(U/mL) | CEA/(ng/mL) | CYFRA 21-1/(ng/mL) | SCC-Ag/(ng/mL) |
---|---|---|---|---|---|
早期NSCLC组 | 64 | 12.75(8.53~26.45) | 2.38(1.52~3.40) | 2.53(1.70~3.55) | 1.20(0.89~1.42) |
正常对照组 | 80 | 9.47(7.32~15.71)* | 1.42(0.82~2.39)* | 1.86(1.39~2.46)* | 1.13(0.90~1.66) |
肺良性疾病组 | 65 | 10.20(7.57~12.35)* | 2.43(1.45~3.48) | 1.72(1.28~3.14)* | 1.10(0.75~1.52) |
组别 | 例数 | CA 19-9/(U/mL) | CEA/(ng/mL) | CYFRA 21-1/(ng/mL) | SCC-Ag/(ng/mL) |
---|---|---|---|---|---|
早期NSCLC组 | 64 | 12.75(8.53~26.45) | 2.38(1.52~3.40) | 2.53(1.70~3.55) | 1.20(0.89~1.42) |
正常对照组 | 80 | 9.47(7.32~15.71)* | 1.42(0.82~2.39)* | 1.86(1.39~2.46)* | 1.13(0.90~1.66) |
肺良性疾病组 | 65 | 10.20(7.57~12.35)* | 2.43(1.45~3.48) | 1.72(1.28~3.14)* | 1.10(0.75~1.52) |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
Ala | 0.656(0.587~0.720) | 489.69 μmol/L | 65.62 | 62.07 | 0.29 |
Glu | 0.663(0.595~0.727) | 189.63 μmol/L | 87.50 | 41.38 | 0.31 |
Pro | 0.620(0.551~0.686) | 226.39 μmol/L | 35.94 | 83.45 | 0.19 |
Val | 0.663(0.595~0.727) | 312.40 μmol/L | 53.13 | 72.41 | 0.26 |
Cit | 0.709(0.642~0.770) | 29.15 μmol/L | 81.25 | 53.10 | 0.34 |
Orn | 0.699(0.632~0.760) | 114.68 μmol/L | 89.06 | 44.14 | 0.33 |
CA 19-9 | 0.635(0.566~0.700) | 10.90 U/mL | 64.06 | 60.00 | 0.24 |
CEA | 0.605(0.535~0.672) | 1.22 ng/mL | 84.37 | 35.17 | 0.20 |
CYFRA 21-1 | 0.671(0.603~0.735) | 2.43 ng/mL | 56.25 | 72.41 | 0.29 |
联合检测模型 | 0.808(0.748~0.859) | 0.43 | 64.56 | 88.28 | 0.52 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
Ala | 0.656(0.587~0.720) | 489.69 μmol/L | 65.62 | 62.07 | 0.29 |
Glu | 0.663(0.595~0.727) | 189.63 μmol/L | 87.50 | 41.38 | 0.31 |
Pro | 0.620(0.551~0.686) | 226.39 μmol/L | 35.94 | 83.45 | 0.19 |
Val | 0.663(0.595~0.727) | 312.40 μmol/L | 53.13 | 72.41 | 0.26 |
Cit | 0.709(0.642~0.770) | 29.15 μmol/L | 81.25 | 53.10 | 0.34 |
Orn | 0.699(0.632~0.760) | 114.68 μmol/L | 89.06 | 44.14 | 0.33 |
CA 19-9 | 0.635(0.566~0.700) | 10.90 U/mL | 64.06 | 60.00 | 0.24 |
CEA | 0.605(0.535~0.672) | 1.22 ng/mL | 84.37 | 35.17 | 0.20 |
CYFRA 21-1 | 0.671(0.603~0.735) | 2.43 ng/mL | 56.25 | 72.41 | 0.29 |
联合检测模型 | 0.808(0.748~0.859) | 0.43 | 64.56 | 88.28 | 0.52 |
1 |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
DOI URL |
2 |
SHI J F, WANG L, WU N, et al. Clinical characteristics and medical service utilization of lung cancer in China,2005-2014:overall design and results from a multicenter retrospective epidemiologic survey[J]. Lung Cancer, 2019, 128:91-100.
DOI URL |
3 | 孙大强, 陈平雁, 刘伦旭, 等. 11 958例Ⅰ-ⅢA期非小细胞肺癌手术患者不同随访方式5年生存率比较的多中心真实世界研究[J]. 中国胸心血管外科临床杂志, 2021, 28(6):615-622. |
4 |
张敏璐, 吴春晓, 龚杨明, 等. 上海人群肺癌生存率分析[J]. 中国癌症杂志, 2017, 27(5):326-333.
DOI |
5 | CHEN Y, MA Z, MIN L, et al. Biomarker identification and pathway analysis by serum metabolomics of lung cancer[J]. Biomed Res Int, 2015, 2015:183624. |
6 |
MAEDA J, HIGASHIYAMA M, IMAIZUMI A, et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer:a case control study[J]. BMC Cancer, 2010, 10:690.
DOI URL |
7 |
KLUPCZYNSKA A, DEREZISKI P, DYSZKIEWICZ W, et al. Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population[J]. Lung Cancer, 2016, 100:71-76.
DOI URL |
8 |
SHINGYOJI M, IIZASA T, HIGASHIYAMA M, et al. The significance and robustness of a plasma free amino acid(PFAA) profile-based multiplex function for detecting lung cancer[J]. BMC Cancer, 2013, 13:77.
DOI URL |
9 |
KIM H J, JANG S H, RYU J S, et al. The performance of a novel amino acid multivariate index for detecting lung cancer:a case control study in Korea[J]. Lung Cancer, 2015, 90(3):522-527.
DOI URL |
10 | 邹琛, 徐润灏, 张泓, 等. 小分子代谢物在肺癌和肺炎鉴别诊断中的潜在作用[J]. 上海交通大学学报(医学版), 2020, 40(8):1041-1047. |
11 | 陈永亮, 姚弘, 林永财, 等. 原发性肺癌患者血清氨基酸测定及临床意义[J]. 上海医学检验杂志, 1998, 13(4):199. |
12 | 莫靓, 韦兵, 梁任技, 等. 不同病理分期肺腺癌患者血清代谢组学研究[J]. 基因组学与应用生物学, 2020, 39(2):830-836. |
13 |
KALUARACHCHI M, BOULANGÉ C L, KARAMAN I, et al. A comparison of human serum and plasma metabolites using untargeted 1H NMR spectroscopy and UPLC-MS[J]. Metabolomics, 2018, 14(3):32.
DOI URL |
14 |
JING F, HU X, CAO Y, et al. Discriminating gastric cancer and gastric ulcer using human plasma amino acid metabolic profile[J]. IUBMB Life, 2018, 70(6):553-562.
DOI PMID |
15 | 史祚秀, 冯杰, 刘洋, 等. 结直肠癌患者血浆代谢物水平研究[J]. 中国现代医学杂志, 2020, 30(24):35-40. |
16 |
POILLET-PEREZ L, XIE X, ZHAN L, et al. Autophagy maintains tumour growth through circulating arginine[J]. Nature, 2018, 563(7732):569-573.
DOI URL |
17 |
YUZHALIN A E. Citrullination in cancer[J]. Cancer Res, 2019, 79(7):1274-1284.
DOI PMID |
18 |
TOHME S, YAZDANI H O, AL-KHAFAJI A B, et al. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress[J]. Cancer Res, 2016, 76(6):1367-1380.
DOI PMID |
19 |
NICKLIN P, BERGMAN P, ZHANG B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy[J]. Cell, 2009, 136(3):521-534.
DOI PMID |
20 |
SEKIYA K, SAKAI T, HOMMA S, et al. Pulmonary tuberculosis accompanied by a transient increase in serum carcinoembryonic antigen level with tuberculous empyema drainage[J]. Intern Med, 2007, 46(21):1795-1798.
DOI URL |
21 |
NAKAYAMA M, SATOH H, ISHIKAWA H, et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases[J]. Chest, 2003, 123(6):2001-2006.
PMID |
22 |
TRAPÉ J, FILELLA X, ALSINA-DONADEU M, et al. Increased plasma concentrations of tumour markers in the absence of neoplasia[J]. Clin Chem Lab Med, 2011, 49(10):1605-1620.
DOI PMID |
23 |
AJONA D, REMIREZ A, SAINZ C, et al. A model based on the quantification of complement C4c,CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer[J]. Transl Res, 2021, 233:77-91.
DOI URL |
24 |
WADOWSKA K, BASIAK P, RZECHONEK A, et al. New insights on old biomarkers involved in tumor microenvironment changes and their diagnostic relevance in non-small cell lung carcinoma[J]. Biomolecules, 2021, 11(8):1208.
DOI URL |
25 | 彭焦武, 孙承谋. miR-124a和miR-449a对非小细胞肺癌的诊断价值[J]. 检验医学, 2021, 36(1):34-38. |
26 |
XIE Y, MENG W Y, LI R Z, et al. Early lung cancer diagnostic biomarker discovery by machine learning methods[J]. Transl Oncol, 2021, 14(1):100907.
DOI URL |
[1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[2] | CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639. |
[3] | YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346. |
[4] | SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351. |
[5] | Expert Group on the Consensus on Androgen Testing in Polycystic Ovary Syndrome China Association for Promotion of Health Science and Technology-Fertility Protection and Preservation Committee. Consensus on androgen testing in polycystic ovary syndrome [J]. Laboratory Medicine, 2023, 38(3): 203-208. |
[6] | YANG Xiaodong, LI Quanle, PAN Qingqing, ZHOU Jing, XIE Yangmin, ZOU Jihua, SHEN Min, ZHANG Man. Establishment and performance evaluation of candidate reference measurement procedure for the determination of immunosuppressive drugs in human whole blood by ID-LC-MS/MS [J]. Laboratory Medicine, 2023, 38(3): 215-222. |
[7] | GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine:from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312. |
[8] | ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355. |
[9] | XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55. |
[10] | MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59. |
[11] | LI Bingling, CHENG Yating, ZHAO Beibei, SHE Xuhui, DONG Heng, YU Mujun. Evaluation of surrogate matrices for serum 25-hydroxyvitamin D calibrators by LC-MS/MS [J]. Laboratory Medicine, 2021, 36(2): 213-218. |
[12] | XU Runhao, ZOU Chen, ZHANG Jie, LI Min, ZHANG Shulin. Application of serum bile acid spectrum in the differential diagnosis of pneumonia and lung cancer [J]. Laboratory Medicine, 2021, 36(1): 1-7. |
[13] | PENG Jiaowu, SUN Chengmou. Diagnostic value of miR-124a and miR-449a in plasma of non-small cell lung cancer [J]. Laboratory Medicine, 2021, 36(1): 34-38. |
[14] | WANG Zijin, ZHANG Xiaoying. Role of apolipoprotein M in the proliferation,migration and invasion of non-small cell lung cancer A549 cells [J]. Laboratory Medicine, 2020, 35(9): 937-942. |
[15] | YUAN Shiyang, LIU Chuan, OUYANG Xiaochun, XIE Junping, HE Rongzhi, LI Lixiang, ZOU Yeqing. Clinical significance of detecting plasma EGFR T790M gene mutation in patients with NSCLC by 3D digital PCR [J]. Laboratory Medicine, 2020, 35(8): 806-810. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||